Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Mato, A.; Nabhan, C.; C. Thompson, Meghan; Lamanna, N.; Brander, D.; Hill, B.; Howlett, C.; Skarbnik, A.; Cheson, B.; Zent, C.; Pu, J.; Kiselev, P.; Goy, A.; Claxton, D.; M Isaac, Krista; Kennard, K.; Timlin, C.; Landsburg, D.; Winter, A.; Nasta, S.; H. Bachow, S.; Schuster, S.; Dorsey, C.; Svoboda, J.; Barr, P.; Ujjani, C.

doi:10.3324/haematol.2017.182907

Public

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Published in Haematologica • Feb 1, 2018

Authors:

A. Mato

C. Nabhan

Meghan C. Thompson

Abstract

Clinical trials that led to ibrutinib’s approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy. Reasons for discontinuation in clinical practice have not been adequately studied. We conducted a retrospective analysis of c...

View

Open Access

Subject

Medicine

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!